MiMedx Reports Positive CAMPAIGN Trial Interim Results, Enrollment Ongoing

MiMedx Group has announced the publication of interim results from the CAMPAIGN trial, which demonstrate clinical benefit associated with the use of EPIEFFECT compared to standard of care. The study, published in the International Journal of Tissue Repair, is a randomized controlled trial designed to evaluate the performance of EPIEFFECT in treating nonhealing diabetic foot ulcers. Enrollment for the trial is ongoing, with advanced predictive models indicating superior results for EPIEFFECT.